Find Novel Dermatology Drugs in Preclinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KB301

            Therapeutic Area: Dermatology Product Name: KB301

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 25, 2020

            Details:

            KB301 is designed to restore collagen homeostasis locally via directed COL3A1 expression, thereby reconstructing an optimal physiologic environment in the skin to treat wrinkles and other superficial skin defects.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antibiotic,Zinc chelator

            Therapeutic Area: Dermatology Product Name: BioLexa

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 13, 2020

            Details:

            Study to determine the safety, tolerability, pharmacokinetics and efficacy of twice daily application of topical BioLexa in healthy subjects and patients with mild to moderate atopic dermatitis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VNLG 152

            Therapeutic Area: Dermatology Product Name: VNLG 152

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Isoprene Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement July 31, 2020

            Details:

            Isoprene Pharmaceuticals will acquire rights to Hoth's VNLG-152, a novel retinamides (Retinoic acid metabolism blocking agents, or RAMBAs) for the treatment of dermatological diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: $2,000.0 million Upfront Cash: $150.0 million

            Deal Type: Partnership July 09, 2020

            Details:

            Kymera will advance the IRAK4 program through Phase 1 clinical trials; Sanofi will assume clinical development and commercialization responsibilities thereafter. Sanofi will lead all clinical development activities for the second program.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATI-1777

            Therapeutic Area: Dermatology Product Name: ATI-1777

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 07, 2020

            Details:

            Aclaris plans to initiate a Phase 1/2a multicenter, randomized, double-blind, vehicle-controlled trial to investigate the safety, tolerability, pharmacokinetics, and efficacy of topically applied ATI-1777 in subjects with moderate to severe AD in the second half of 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): WEG232

            Therapeutic Area: Dermatology Product Name: WEG232

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: George Washington University

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 16, 2020

            Details:

            Hoth Therapeutics has expanded its research agreement with the George Washington University to explore the potential use of WEG232 for topical and/or systemic therapy to counter the dermatological related side-effects of chemotherapy and immunotherapy in cancer patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VNLG 152

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 03, 2020

            Details:

            Management provides pipeline update for assets including BioLexa Platform (Dermatological), VNLG-152 (Dermatological), WEG-232 (Dermatological), VaxCelerate (COVID-19), Novel Peptide Therapeutic (COVID-19), AEA-loaded Z-pods™ (Lupus), Exon Skipping Approach (Allergic Disease).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 03, 2020

            Details:

            Kymera is developing potent and selective orally administered IRAK4 degraders for the treatment of toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven autoimmune and autoinflammatory diseases.

            Chelexa Biosciences

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antimicrobial therapy

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hoth Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement May 18, 2020

            Details:

            Hoth Therapeutics has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, antimicrobial therapy focused on treating atopic dermatitis. The agreement is an extension to the previously executed sublicense agreement with Chelexa Biosciences.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tetrahydrocannabinol,Cannabidiol

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 16, 2020

            Details:

            PP004 will be used for management of pain and itch in EB, symptoms that, despite a range of current treatment strategies, significantly affect the quality of life in EB patients.

            PharmaCompass